FIELD: immunology.
SUBSTANCE: disclosed are monoclonal antibodies against human DNAM-1 or fragments thereof, nucleic acid, an expression vector, a host cell and a pharmaceutical composition.
EFFECT: present invention can find further application in prevention of graft versus host reaction and transplant rejection.
11 cl, 23 dwg, 1 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY | 2012 |
|
RU2715642C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
